Gelonghui January 7｜Research Reports from China International Capital Corporation indicate that SH PHARMA (601607.SH) acquisition is expected to enrich the Traditional Chinese Medicine matrix, with new digestive products approved for market release. This acquisition is expected to boost the company's profits and enhance SH PHARMA's evidence-based medical and academic promotion capabilities. It is believed that the successful experience of Muscone Heart-Preserving Pills will serve as a reference for the secondary development of potential varieties in the field of cardiovascular and cerebrovascular diseases, such as Coronary Heart Ning Tablets, Silver Ketone Ester series, and Yang Xin Shi Tablets. In addition, as of December 2024, Shanghai and Hong Pharmaceuticals has a professional academic promotion team of nearly 2,300 people. Furthermore, it is believed that New China Life Insurance is bullish on the company's long-term development stability, expecting to hold shares long-term to share in the growth dividends of the Industry. Insurance funds acquiring stakes are also likely to introduce patient capital, reducing the volatility of the company's stock price. Maintaining a rating of outperforming the Industry for A-shares, with a Target Price of 23.3 yuan.